|
Novartis and collaborators discover new dual-acting class of antimalarial compounds
|
17 November 2011 |
|
Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals
|
09 November 2011 |
|
Novartis achieves strong third quarter financial performance and pipeline progress
|
26 October 2011 |
|
AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
|
25 October 2011 |
|
Novartis drug Gilenya® (fingolimod) has more than 20,000 patient-years of exposure
|
18 October 2011 |
|
New Novartis data show potential of respiratory portfolio
|
27 September 2011 |
|
New Data from Phase III IMPRES Clinical Trial
|
26 September 2011 |
|
Novartis associates participate in first company-wide health and well-being initiative
|
20 September 2011 |
|
Novartis increases growth potential through integration of Alcon
|
13 September 2011 |
|
Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors
|
05 September 2011 |